Is Interoperability Tech Worth the Investment? Experts Say Yes for 3 Reasons

Is Interoperability Tech Worth the Investment? Experts Say Yes for 3 Reasons

Editor’s note: This story is based on discussions at Abarca Forward, a conference in San Juan, Puerto Rico, hosted by Abarca, a pharmacy benefit manager. MedCity News’ Editor-in-Chief Arundhati Parmar and Senior Reporter Katie Adams were invited to attend and speak at the conference. All travel and related expenses for the team were covered by Abarca. However, company officials had no input in editorial coverage. 
In order for the U.S. healthcare system to operate smoothly, various stakeholders must cooperate with one another and share data seamlessly. But this notion is far from being achieved — the industry is still seriously plagued by…

Continue Reading
Report: Pharma R&D ROI Falls to Lowest Level in 13 Years

Report: Pharma R&D ROI Falls to Lowest Level in 13 Years

What You Should Know:– Deloitte Centre for Health Solutions releases its thirteenth annual report, ‘Seize the Digital Momentum: Measuring the return from pharmaceutical innovation 2022’ that explores the performance of the biopharmaceutical industry (bio Pharma) and its ability to generate returns from investment in innovative new medicines.– Since 2021, much of the world has successfully adjusted to life where COVID-19 is more endemic as vaccines and treatments reduced the risk and severity of illness, however geopolitical turmoil and a global cost-of-living crisis have continued to drive serious instability in the health landscape.Pharmaceutical Innovation – Trends and Insights At a GlanceThis is…

Continue Reading
Medication risk analysis company MDI Health raises $20M

Medication risk analysis company MDI Health raises $20M

Healthcare analytics company MDI Health scored $20 million in Series A funding, bringing the company’s total funding to $26 million.Intel Capital led the round, with participation from Maverick Ventures Israel, alongside existing investors Fresh.Fund, Arc Impact, Hanaco Ventures, Jumpspeed Ventures, former Optum senior vice president Richard Montwill, Welltech Ventures and Basad Ventures.
Yoni Greifman, Intel Capital’s investment director, will join MDI’s board of directors.
WHAT IT DOES
Israel-based MDI offers an AI-enabled tool that provides medication risk analysis based on a patient’s medical records with the aim of preventing adverse drug reactions.
The funds will help the company scale its U.S. and Israeli research and…

Continue Reading